BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21999609)

  • 1. Development of anti-HIV activity models of lysine sulfonamide analogs: a QSAR perspective.
    Muthukumaran R; Sangeetha B; Amutha R; Mathur PP
    Curr Comput Aided Drug Des; 2012 Mar; 8(1):70-82. PubMed ID: 21999609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
    Santos-Filho OA; Hopfinger AJ
    J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors.
    Fatemi MH; Heidari A; Gharaghani S
    J Theor Biol; 2015 Mar; 369():13-22. PubMed ID: 25600056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
    Saranya N; Selvaraj S
    Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D; Liu MS; Ji B; Hwang KC; Huang Y
    Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of conceptual DFT descriptors and docking scores on the QSAR models of HIV protease inhibitors.
    Srivastava HK; Choudhury C; Sastry GN
    Med Chem; 2012 Sep; 8(5):811-25. PubMed ID: 22741804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease.
    Nalam MN; Peeters A; Jonckers TH; Dierynck I; Schiffer CA
    J Virol; 2007 Sep; 81(17):9512-8. PubMed ID: 17596316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding the structural requirements of diverse HIV-1 protease inhibitors using multiple QSAR modelling for lead identification.
    Halder AK
    SAR QSAR Environ Res; 2018 Nov; 29(11):911-933. PubMed ID: 30332922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
    Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
    Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype dependent QSAR for HIV-1 protease inhibition.
    Boutton CW; De Bondt HL; De Jonge MR
    J Med Chem; 2005 Mar; 48(6):2115-20. PubMed ID: 15771454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
    Chetty S; Bhakat S; Martin AJ; Soliman ME
    J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure based prediction of binding affinity of human immunodeficiency virus-1 protease inhibitors.
    Kulkarni SS; Kulkarni VM
    J Chem Inf Comput Sci; 1999; 39(6):1128-40. PubMed ID: 10614027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How good are ensembles in improving QSAR models? The case with eCoRIA.
    Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
    J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models.
    Jayatilleke PR; Nair AC; Zauhar R; Welsh WJ
    J Med Chem; 2000 Nov; 43(23):4446-51. PubMed ID: 11087569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches.
    Srivastava HK; Sastry GN
    J Chem Inf Model; 2012 Nov; 52(11):3088-98. PubMed ID: 23121465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
    Chen J; Peng C; Wang J; Zhu W
    Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.